Polyradiculoneuropathy Chronic Inflammatory Demyelinating

• EMA approval · 2026-06-05
  EMA Authorised: HyQvia (human normal immunoglobulin) — Baxalta Innovations GmbH

  The EMA has authorised HyQvia (human normal immunoglobulin) from Baxalta Innovations GmbH for use in immunologic deficiency syndromes and re…

• CLINICAL_TRIALS trial_result · 2018-10-02
  Clinical Trial Update: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 3]

  Phase 3 extension study evaluating maintenance subcutaneous immunoglobulin (IgPro20) in CIDP has been completed with posted results.